Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Andrea Nicolini, Angelo Carpi, Paola Ferrari, Riccardo Morganti, Valentina Mazzotti, Vivian Barak & Michael J Duffy. (2018) An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer. Cancer Management and Research 10, pages 6879-6886.
Read now
Read now
Wonshik Han, Hoon Kim, Seung-Yup Ku, Seok Hyun Kim, Young Min Choi, Jung Gu Kim & Shin Yong Moon. (2013) Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer. Gynecological Endocrinology 29:1, pages 16-19.
Read now
Read now
Articles from other publishers (23)
Ximena Briceño Morales, Andrea Zuluaga Liberato, Clara Briceño Morales, Luis Hernán Guzmán Abi-Saab, Jesús Oswaldo Sánchez Castillo, Ricardo Brugés Maya, Carlos Lehmann Mosquera, Mauricio García Mora, Javier Ángel Aristizabal, Iván Fernando Mariño Lozano, Carlos Alfonso Duarte-Torres, Fernando Contreras Mejía, Eduardo Alfonso Rojas Andrade & Sandra Esperanza Diaz Casas. (2023) Seguimiento de la paciente con diagnóstico de cáncer de mama. Revisión de la evidencia y abordaje terapéutico en el Instituto Nacional de Cancerología - Colombia. Revista Colombiana de Cancerología 27:Supl. 1, pages 52-71.
Crossref
Crossref
Hanna Huebner, Lothar Häberle, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Visnja Fink, Fabienne Schochter, Inga Bekes, Sven Mahner, Julia Jückstock, Naiba Nabieva, Andreas Schneeweiss, Hans Tesch, Sara Brucker, Jens-Uwe Blohmer, Tanja Fehm, Georg Heinrich, Mahdi Rezai, Matthias Beckmann, Peter Fasching, Wolfgang Janni & Brigitte Rack. (2022) MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers 14:7, pages 1721.
Crossref
Crossref
David W. Cescon, Kevin Kalinsky, Heather A. Parsons, Karen Lisa Smith, Patricia A. Spears, Alexandra Thomas, Fengmin Zhao & Angela DeMichele. (2022) Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Frontiers in Oncology 11.
Crossref
Crossref
Raluca-Ioana Stefan-van Staden, Ruxandra-Maria Ilie-Mihai, Florina Pogacean & Stela Maria Pruneanu. (2020) Needle stochastic sensors for on-site fast recognition and quantification of biomarkers for gastric cancer in biological samples. New Journal of Chemistry 44:46, pages 20203-20211.
Crossref
Crossref
Alexandre Perrier, Pierre-Yves Boelle, Yves Chrétien, Joseph Gligorov, Jean-Pierre Lotz, Didier Brault, Eva Comperat, Guillaume Lefèvre & Mathieu Boissan. (2020) An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PLOS ONE 15:1, pages e0227356.
Crossref
Crossref
Ryan J O Dowling, Kevin Kalinsky, Daniel F Hayes, Francois-Clement Bidard, David W Cescon, Sarat Chandarlapaty, Joseph O Deasy, Mitch Dowsett, Robert J Gray, N Lynn Henry, Funda Meric-Bernstam, Jane Perlmutter, George W Sledge, Scott V Bratman, Lisa A Carey, Martin C Chang, Angela DeMichele, Marguerite Ennis, Katarzyna J Jerzak, Larissa A Korde, Ana Elisa Lohmann, Eleftherios P Mamounas, Wendy R Parulekar, Meredith M Regan, Daniel Schramek, Vuk Stambolic, Mangesh A Thorat, Timothy J Whelan, Antonio C Wolff, Jim R Woodgett, Joseph A Sparano & Pamela J Goodwin. (2019) Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum 3:4.
Crossref
Crossref
Joseph A SparanoN Lynn Henry. (2019) Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. JNCI: Journal of the National Cancer Institute 111:4, pages 339-341.
Crossref
Crossref
Joseph Sparano, Anne O’Neill, Katherine Alpaugh, Antonio C. Wolff, Donald W. Northfelt, Chau T. Dang, George W. Sledge & Kathy D. Miller. (2018) Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer. JAMA Oncology 4:12, pages 1700.
Crossref
Crossref
Michael J Duffy, Enda W McDermott & John Crown. (2018) Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Tumor Biology 40:5, pages 101042831877616.
Crossref
Crossref
Yue Yang, Huijuan Zhang, Mingyan Zhang, Qingwei Meng, Li Cai & Qingyuan Zhang. (2017) Elevation of serum CEA and CA15‑3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients. Oncology Letters.
Crossref
Crossref
Srinidi Mohan, Nancy Moua & Lisa Harding. (2016) N w-hydroxy-l-arginine as a novel ethnic specific indicator of estrogen-negative breast cancer. Amino Acids 48:11, pages 2693-2698.
Crossref
Crossref
Jean-Marc Riedinger, Vincent Goussot, Isabelle Desmoulins, Véronique Lorgis, Charles Coutant, Françoise Beltjens, Sarab Lizard & Pierre Fumoleau. (2016) ACE et diagnostic précoce de récidive dans les différents sous-types moléculaires de cancer du sein : comparaison au CA 15-3. Bulletin du Cancer 103:5, pages 434-443.
Crossref
Crossref
P. Bonnier. 2016. Cancer du Sein. Cancer du Sein
203
210
.
Hong-Tai Chang, Chin Hu, Yu-Li Chiu, Nan-Jing Peng & Ren-Shyan Liu. (2014) Role of 2-[18F] Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in the Post-Therapy Surveillance of Breast Cancer. PLoS ONE 9:12, pages e115127.
Crossref
Crossref
Mariarosaria Incoronato, Peppino Mirabelli, Onofrio Catalano, Marco Aiello, Chiara Parente, Andrea Soricelli & Emanuele Nicolai. (2014) CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer 14:1.
Crossref
Crossref
L. N. Henry, D. F. Hayes, S. D. Ramsey, G. N. Hortobagyi, W. E. Barlow & J. R. Gralow. (2014) Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. JNCI Journal of the National Cancer Institute 106:4, pages dju034-dju034.
Crossref
Crossref
Ann Christina Pedersen, Patricia Diana Sørensen, Erik Hugger Jacobsen, Jonna Skov Madsen & Ivan Brandslund. (2013) Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clinical Chemistry and Laboratory Medicine 51:7.
Crossref
Crossref
Aysegul Ilhan-Mutlu, Ludwig Wagner, Georg Widhalm, Adelheid Wöhrer, Sophie Bartsch, Thomas Czech, Harald Heinzl, Fritz Leutmezer, Daniela Prayer, Christine Marosi, Wolfgang Base & Matthias Preusser. (2012) Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review 36:1, pages 45-56.
Crossref
Crossref
Jun Ma, Di‐Xian Luo, Chenfei Huang, Yi Shen, Yiwen Bu, Stephen Markwell, John Gao, Jianghua Liu, Xuyu Zu, Zhe Cao, Zachary Gao, Fengmin Lu, Duan‐Fang Liao & Deliang Cao. (2012) AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. International Journal of Cancer 131:6.
Crossref
Crossref
Laura Evangelista, Anna Rita Cervino, Cristina Ghiotto, Adil Al-Nahhas, Domenico Rubello & Pier Carlo Muzzio. (2012) Tumor Marker–Guided PET in Breast Cancer Patients—A Recipe for a Perfect Wedding. Clinical Nuclear Medicine 37:5, pages 467-474.
Crossref
Crossref
Gaia Grassetto, Adriano Fornasiero, Daniele Otello, Giorgio Bonciarelli, Elena Rossi, Ottorino Nashimben, Anna Maria Minicozzi, Giorgio Crepaldi, Felice Pasini, Enzo Facci, Giovanni Mandoliti, Maria Cristina Marzola, Adil Al-Nahhas & Domenico Rubello. (2011) 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study. European Journal of Radiology 80:3, pages 828-833.
Crossref
Crossref
Laura Evangelista, Zora Baretta, Lorenzo Vinante, Anna Rita Cervino, Michele Gregianin, Cristina Ghiotto, Fernando Bozza & Giorgio Saladini. (2011) Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT? Results from small population with previous breast cancer. Annals of Nuclear Medicine 25:7, pages 469-477.
Crossref
Crossref
Peter H. Wiernik, Dahlia Elkadi, Alvaro Luongo-Cespedes, Julio Battistoni, Silvina Rossi, Susana Caceres, Raul Platero, Norma Piriz & Alvaro Lamas. (2010) Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: preliminary results in the United States. Medical Oncology 28:1, pages 67-70.
Crossref
Crossref